HOME >> BIOLOGY >> NEWS
For the longest distance runner, that tired feeling may not be due to central fatigue

iology.

Methodology

Nine healthy male subjects (age 41.6 5.9 years; mass 152 15 lbs.; height 5 ft., 9 inches four inches; body fat 10.6 2.6 percent), all regular competitors in running or triathlon events, were enrolled in the study. The maximal twitches for knee extensors (KE) and plantar flexors (PF) were both examined before and after the 40-mile race using a bicycle ergometer. This testing device uses the inertia of a flywheel to provide resistance during both shortening (concentric) and lengthening (eccentric) muscle actions. This measures isometric, concentric, and eccentric muscle actions, assessing strength and velocity of different types of muscle actions.

The first session, when subjects were in a nonfatigued state, was conducted in the week prior to the ultramarathon. The test started with a 10 minute warm-up on the bicycle ergometer. The second session was undertaken in a fatigued state, two minutes after the race, and required 20 minutes on the bicycle ergometer.

During both sessions, the KE and PF were given electrical stimulation to determine muscle contractile measurements. During the test in the nonfatigued stage, the intensity was increased until there was no further increase in the height of the muscle twitch (involuntary contraction) or the amplitude of the M wave (electrically evoked muscle potential). The same stimulus level was used during the fatigued stage of the experiment.

Results

Maximal voluntary contractions and maximal voluntary activation decreased significantly after the ultramarathon (a decline of 30.2 18.0 percent and 27.7 13.0 percent, respectively). Surprisingly, peak twitch increased after the ultramarathon from 15.8 6.3 to 19.7 3.3 Nm) and from 131.9 21.2 to 157.1 35.9 Nm for KE. Also, shorter contraction and half-relaxation times were observed for both muscles. The compound muscle action potentials (M wave) were not significa
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
14-Mar-2002


Page: 1 2 3

Related biology news :

1. ICSI and IVF are safe results from worlds largest, longest running study
2. Yellowstones long-distance travelers in trouble, study says
3. Long-distance command sends human growth hormone into action
4. Action at a distance in the hyperoxic eye
5. Misfiring proteins tied to inflammation and sick feeling of type 2 diabetics
6. Scientists sequence genome of kind of organism central to biospheres carbon cycle
7. Genes may be central to cocaine addiction
8. Newborn lambs central heating system could aid fat busting in humans
9. Visualizing the central dogma
10. A link between thimerosal and the brain: Can vaccines affect central nervous system function?
11. Virginia Bioinformatics Institute central to Regional Center of Excellence

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: